The event of pseudoprogression is rare in patients with MSI-high metastatic colorectal cancer receiving immune checkpoint inhibitors. In this response to the Letter to the Editor by Colle et al, we highlight that the timing of disease re-assessment may influence the incidence of pseudoprogression, with early assessments being associated with higher incidence. Such dynamics should be considered when interpreting the efficacy of treatment.
Keywords: gastrointestinal neoplasms; immunotherapy; tumor biomarkers.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.